Co-leader, Melanoma Disease Group
Georgetown Lombardi Comprehensive Cancer Center
Medstar Georgetown University Hospital
Associate Managing Editor
Senior Clinical Editor
Editorial Director, Hematology/Oncology
This program is intended for oncologists, hematologists, and other healthcare professionals who care for patients with cancer.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 16, 2016, through November 15, 2017:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.
Immune checkpoint inhibitors (ICIs) have expanded treatment options for patients who cannot tolerate chemotherapy. Read my thoughts on using ICIs in clinical practice, as well as some of the most promising salvage strategies for patients who progress on them.
Results from KEYNOTE-042 trial of first-line pembrolizumab vs standard chemotherapy in advanced NSCLC with PD-L1 TPS ≥ 1% from ASCO 2018 reported by Clinical Care Options (CCO).
KEYNOTE-407 data on adding pembrolizumab to platinum-based chemotherapy in patients with untreated metastatic squamous NSCLC from ASCO 2018 reported by Clinical Care Options (CCO).
Downloadable PDF with approved immunotherapies, complementary diagnostics, and other available assays for PD-L1 in multiple malignancies.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.